Trilaciclib (G1T28): A cyclin dependent kinase 4/6 inhibitor, in combination with etoposide and carboplatin (EP) for extensive stage small cell lung cancer (ES-SCLC) -Phase 1b results.

被引：6

作者：

Lima, Caio Max S. Rocha

Roberts, Patrick J.

Priego, Victor M.

Divers, Stephen G.

Thomas, Melanie B.

Boccia, Ralph V.

Stabler, Katie

Andrews, Elizabeth

Malik, Rajesh K.

Aljumaily, Raid

Hamm, John Turner

Chiu, Vi Kien

Richards, Donald A.

Nikolinakos, Petros

Hussein, Maen A.

Schuster, Steven Robert

Hoyer, Robert John

Shapiro, Geoffrey

Dragnev, Konstantin H.

Owonikoko, Taofeek Kunle

机构：

[1] Gibbs Canc Ctr & Res Inst, Spartanburg, SC USA

[2] G1 Therapeut Inc, Res Triangle Pk, NC USA

[3] Ctr Canc & Blood Disorders, Bethesda, MD USA

[4] Genesis Canc Ctr, Hot Springs, AR USA

[5] Med Univ South Carolina, Charleston, SC 29425 USA

[6] PPD, Wilmington, NC USA

[7] Univ Oklahoma, Med Ctr, Oklahoma City, OK USA

[8] Norton Healthcare, Louisville, KY USA

[9] Univ New Mexico, Comprehens Canc Ctr, Albuquerque, NM 87131 USA

[10] Texas Oncol, Tyler, TX USA

[11] Univ Canc & Blood Ctr LLC, Athens, GA USA

[12] Florida Canc Specialists & Res Inst, Leesburg, FL USA

[13] Univ Colorado, Ft Collins, CO USA

[14] Mem Sloan Kettering Canc Ctr, Colorado Springs, CO USA

[15] Dana Farber Canc Inst, Boston, MA 02115 USA

[16] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA

[17] Emory Univ, Atlanta, GA 30322 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷

关键词：

D O I：

10.1200/JCO.2017.35.15_suppl.8568

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

8568

引用

页数：5

共 50 条

[21] Phase 1/2 study of veliparib (V) combined with carboplatin (Cb) and etoposide (E) in patients (pts) with extensive-stage disease (ED) small cell lung cancer (SCLC) and other solid tumors: Phase 1 results.
Atrafi, Florence
Groen, Harry J. M.
Byers, Lauren Averett
Garralda, Elena
Lolkema, Martijn P.
Sangha, Randeep S.
Ramirez, Santiago Viteri
Chae, Young Kwang
Camidge, D. Ross
Gabrail, Nashat Y.
Waskiewicz, Tina
Hu, Beibei
Xu, Tu
Nuthalapati, Silpa
Hoening, Elizabeth
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[22] A randomized phase II study of carboplatin (C) and etoposide (E) with or without pan-BCL-2 antagonist obatoclax (Ob) in extensive-stage small cell lung cancer (ES-SCLC).
Langer, C. J.
Albert, I.
Kovacs, P.
Blakely, L. J.
Pajkos, G.
Petrov, P.
Somfay, A.
Szczesna, A.
Zatloukal, P.
Kazarnowicz, A.
Moezi, M. M.
Schreeder, M. T.
Schnyder, J.
Berger, M. S.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[23] Updated results of phase 1b study of tarextumab (TRXT, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC).
Chiang, Anne C.
Rudin, Charles M.
Spira, Alexander I.
Jotte, Robert M.
Gadgeel, Shirish M.
Mita, Alain C.
Hart, Lowell L.
Gluck, William Larry
Liu, Stephen V.
Kapoun, Ann M.
Xu, Lu
Hill, Dawn
Zhou, Lei
Dupont, Jakob
Spigel, David R.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[24] Atezolizumab (ATZ) in combination with carboplatin (Cb) and etoposide (Eto) in the treatment of patients with previously untreated extensive-stage small cell lung cancer (ES-SCLC): A multicenter, phase IIIb, single arm, safety study (MAURIS trial)
Martini, G.
Bria, E.
Gridelli, C.
Garassino, M. C.
Ardizzoni, A.
De Marinis, F.
ANNALS OF ONCOLOGY, 2020, 31 : S1044 - S1045
[25] Expression analysis of Fuc-GM1 ganglioside in first-line therapy for extensive-stage small cell lung cancer (ES-SCLC) with BMS-986012, nivolumab, and carboplatin-etoposide
O'Byrne, K. J.
Zhang, Y.
Ouyang, J.
Chou, W-C.
Chou, C-H.
Wu, J.
Adelakun, O.
Hollmann, T.
Zeng, J. A.
Corrella, L.
Metzler, M.
Green, C.
Sarmiento, R.
Lees, E.
Liu, Y.
Ojalvo, L.
Wu, B.
ANNALS OF ONCOLOGY, 2024, 35 : S1069 - S1070
[26] RANDOMIZED PHASE II TRIAL OF THE PAN BCL-2 ANTAGONIST OBATOCLAX (OB) IN COMBINATION WITH CARBOPLATIN AND ETOPOSIDE (CE) VS CE CHEMOTHERAPY ALONE IN EXTENSIVE STAGE SMALL CELL CARCINOMA OF THE LUNG (ES-SCLC)
Langer, Corey J.
Albert, Istvan
Kovacs, Peter
Blakely, L. Johnetta
Pajkos, Gabor
Petrov, Petar
Somfay, Attila
Szczesna, Aleksandra
Zatloukal, Petr
Kazarnowicz, Andrzej
Moezi, Mehdi
Schreeder, Marshall
Schnyder, Judy
Berger, Mark
JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S310 - S310
[27] Randomized phase II clinical trial of cisplatin/carboplatin and etoposide (CE) alone or in combination with nivolumab as frontline therapy for extensive-stage small cell lung cancer (ES-SCLC): ECOG-ACRIN EA5161.
Leal, Ticiana
Wang, Yating
Dowlati, Afshin
Lewis, DeQuincy Andrew
Chen, Yuanbin
Mohindra, Amit Ramesh
Razaq, Mohammad
Ahuja, Harish G.
Liu, Jijun
King, David M.
Sumey, Christopher Joseph
Ramalingam, Suresh S.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[28] Treatment (tx) characteristics and clinical outcomes in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) treated with carboplatin (carbo) or cisplatin (cis) in combination with etoposide (etop) in US clinical practice
Sebastian, M.
Barlesi, F.
Califano, R.
Mansfield, A. S.
Blackhall, F. H.
Flahavan, E. M.
Davies, J.
Arnold, P.
Morris, S.
Reck, M.
ANNALS OF ONCOLOGY, 2019, 30
[29] Optimizing obatoclax administration schedule: Safety and efficacy of 3-hour versus 24-hour infusion in combination with carboplatin and etoposide for patients with extensive-stage small cell lung cancer (ES-SCLC)
Chiappori, A.
Schreeder, M. T.
Moezi, M. M.
Stephenson, J.
Blakely, L.
Salgia, R.
Chu, Q. S.
Ross, H. J.
Subramaniam, D. S.
Berger, M. S.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[30] Results from KEYNOTE-B98: A phase 1b/2 study of pembrolizumab plus investigational agents in patients with anti-PD-(L)1-refractory extensive-stage small-cell lung cancer (ES-SCLC)
Navarro, Alejandro
Ahn, Myung-Ju
Stevenson, James
Peled, Nir
Kutiel, Talia Shentzer
Huemer, Florian
Kim, Dong-Wan
Casulleras, Maria Jove
Khattak, Adnan
Kowalski, Dariusz
Leighl, Natasha B.
de Marinis, Filippo
Lips, Carolin
Niu, Jiaxin
Huang, Mo
Zhao, Bin
El-Osta, Hazem
Owonikoko, Taofeek
CANCER RESEARCH, 2024, 84 (07)

← 1 2 3 4 5 →